Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


18.03.2024

2 Acta Haematol
1 Am J Hematol
3 Ann Hematol
3 Blood
2 BMC Cancer
2 Bone Marrow Transplant
12 Br J Haematol
1 Cancer
1 Cancer Lett
1 Eur J Immunol
2 Int J Hematol
3 J Clin Oncol
1 J Virol
1 Leuk Lymphoma
4 Leuk Res
4 Leukemia
1 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. BENJAMINI O, Tadmor T, Avigdor A, Gershon R, et al
    Efficacy of preexposure prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia.
    Acta Haematol. 2024 Mar 12. doi: 10.1159/000537690.
    PubMed         Abstract available

  2. SHAPIRA S, Hirschberger N, Ofran Y, Mizrahi B, et al
    The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naive chronic lymphocytic leukemia patients.
    Acta Haematol. 2024 Mar 8. doi: 10.1159/000538055.
    PubMed         Abstract available


    Am J Hematol

  3. TANG H, Jia W, Jia S, Dong R, et al
    A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
    PubMed        


    Ann Hematol

  4. LIU S, Cui Q, Li M, Li Z, et al
    Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
    Ann Hematol. 2024;103:1397-1402.
    PubMed         Abstract available

  5. REN Y, Liu F, Chen X, Zhang X, et al
    Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1345-1351.
    PubMed         Abstract available

  6. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
    Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1187-1196.
    PubMed         Abstract available


    Blood

  7. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
    Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
    Blood. 2024;143:1049-1054.
    PubMed         Abstract available

  8. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
    Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
    Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
    PubMed         Abstract available

  9. AZOULAY E, Maertens J, Lemiale V
    How I manage acute respiratory failure in patients with hematological malignancies.
    Blood. 2024;143:971-982.
    PubMed         Abstract available


    BMC Cancer

  10. SINGH M, Sharma P, Bhatia P, Trehan A, et al
    Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
    BMC Cancer. 2024;24:325.
    PubMed         Abstract available

  11. WANG J, Wang C, Hu A, Yu K, et al
    FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.
    BMC Cancer. 2024;24:326.
    PubMed         Abstract available


    Bone Marrow Transplant

  12. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    PubMed         Abstract available

  13. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed        


    Br J Haematol

  14. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    PubMed         Abstract available

  15. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    PubMed         Abstract available

  16. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    PubMed         Abstract available

  17. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    PubMed        

  18. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    PubMed         Abstract available

  19. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    PubMed         Abstract available

  20. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    PubMed         Abstract available

  21. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    PubMed         Abstract available

  22. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    PubMed        

  23. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    PubMed         Abstract available

  24. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    PubMed        

  25. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    PubMed         Abstract available


    Cancer

  26. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    PubMed         Abstract available


    Cancer Lett

  27. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    PubMed         Abstract available


    Eur J Immunol

  28. PARVEEN M, Karaosmanoglu B, Sucularli C, Uner A, et al
    Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia.
    Eur J Immunol. 2024 Mar 11:e2350717. doi: 10.1002/eji.202350717.
    PubMed         Abstract available


    Int J Hematol

  29. MAEDA Y
    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
    PubMed        

  30. SANO H, Fukushima K, Yano M, Osone S, et al
    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
    Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
    PubMed         Abstract available


    J Clin Oncol

  31. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    PubMed         Abstract available

  32. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    PubMed         Abstract available

  33. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
    PubMed        


    J Virol

  34. GUPTA SS, Maetzig T, Maertens GN, Sharif A, et al
    Correction for Gupta et al., "Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration".
    J Virol. 2024 Mar 13:e0013524. doi: 10.1128/jvi.00135.
    PubMed        


    Leuk Lymphoma

  35. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    PubMed         Abstract available


    Leuk Res

  36. ZHONG S, Kurish H, Walchack R, Li H, et al
    Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2024;139:107468.
    PubMed         Abstract available

  37. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Leuk Res. 2024;139:107467.
    PubMed         Abstract available

  38. PAN L, Li Y, Gao H, Lai X, et al
    Clinical features and management of germline CEBPA-mutated carriers.
    Leuk Res. 2024;138:107453.
    PubMed         Abstract available

  39. SIDI Y, Dong C, Wu Y, Faller DV, et al
    A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
    Leuk Res. 2024;138:107465.
    PubMed         Abstract available


    Leukemia

  40. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
    NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
    Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
    PubMed         Abstract available

  41. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
    Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
    Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
    PubMed        

  42. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
    Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
    Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
    PubMed         Abstract available

  43. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
    PubMed        


    Oncol Rep

  44. TENG Z, Xu S, Lei Q
    [Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB?152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Oncol Rep. 2024;51:66.
    PubMed         Abstract available


    PLoS One

  45. SWANSON AJ, Rogowski VJ, Bishop JA, Walker DM, et al
    CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics.
    PLoS One. 2024;19:e0300477.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.